Dr. Walmsley is a co-founder and managing partner of Logos Capital, a fundamental biotechnology-focused hedge fund that combines in-house data analytics with scientific and clinical expertise to identify transformative therapies in healthcare. Based in San Francisco, Logos combines expertise across medical, scientific, and statistical disciplines to expand the depth of diligence in identifying compelling investment ideas and uncorrelated-market returns. Before Logos, Dr. Walmsley was a Principal at Versant Ventures where he invested in biotechnology companies across four funds totaling over $1.5 billion in AUM. While at Versant, Dr. Walmsley served as a board director, built and launched multiple companies, and was head of business development for Jecure Therapeutics through its acquisition by Roche AG. Dr. Walmsley has more than 60 scientific publications and holds an MD and PhD from Stanford University School of Medicine.